High uptake and long retention in primary and metastatic tumor lesions and a reasonable toxicity profile warrant further investigation of 177Lu-FAP-2286 in prospective clinical studies to systematically evaluate its safety and efficacy and to define the patient population it would most benefit. The gene discussed is FAP; the disease is neoplasm.